Kisspeptin
OtherAlso known as Kisspeptin-10, Metastin, KISS1
Evidence tier
Multiple human trials
1 human trial · 3 reviews
- Researched since
- 1997
- Publications
- 3.8k
- Mean purity
- 99.4%
- Vendors listing
- 16
American Peptides shows the highest mean assayed purity for Kisspeptin at 99.9% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1997 — 29 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
3,829 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.4% across 14 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.49 pts purity across lots, mean label deviation 3.9%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
16 of 16 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
11 of 14 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Kisspeptin?
A peptide encoded by the KISS1 gene that signals through the KISS1 receptor to regulate release of gonadotropin-releasing hormone, central to reproductive endocrinology.
Studied in published research for reproductive hormone signalling and fertility.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human trials of reproductive hormone signalling. PepIndex does not evaluate clinical significance and does not describe administration.
- The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction — Frontiers in endocrinology (2022)
Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2022).
- Metabolic regulation of kisspeptin - the link between energy balance and reproduction — Nature reviews. Endocrinology (2020)
Peer-reviewed article indexed in PubMed, published in Nature reviews. Endocrinology (2020).
- Kisspeptin and Glucose Homeostasis — Seminars in reproductive medicine (2019)
Peer-reviewed article indexed in PubMed, published in Seminars in reproductive medicine (2019).
- Kisspeptin in the Prediction of Pregnancy Complications — Frontiers in endocrinology (2022)
Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2022).
- Kisspeptin as a Behavioral Hormone — Seminars in reproductive medicine (2019)
Peer-reviewed article indexed in PubMed, published in Seminars in reproductive medicine (2019).
- Kisspeptin as a potential biomarker throughout pregnancy — European journal of obstetrics, gynecology, and reproductive biology (2019)
Peer-reviewed article indexed in PubMed, published in European journal of obstetrics, gynecology, and reproductive biology (2019).
- Kisspeptin and its Effect on Mammalian Spermatogensis — Current drug metabolism (2019)
Peer-reviewed article indexed in PubMed, published in Current drug metabolism (2019).
- Kisspeptin and Testicular Function-Is it Necessary? — International journal of molecular sciences (2020)
Peer-reviewed article indexed in PubMed, published in International journal of molecular sciences (2020).
Indexed studies4 human-evidence of 4
- Kisspeptin as a predictor of miscarriage: a systematic review — Systematic review, 2023
A highly accurate serum marker for predicting viable pregnancy needs to be developed. Recent studies have demonstrated that kisspeptin is a potential biomarker for this purpose. This systematic review evaluated the available data in the literature on the role of kisspeptin as a miscarriage biomarker. A literature search was conducted in the PubMed/Medline, Embase, Web of Science, and Scopus databases using the following keywords: (kisspeptin) AND (miscarriage OR pregnancy los…
- Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women — Human — controlled trial, 2021
The ideal therapy for endometriosis (EM) and uterine fibroids (UFs) would suppress estrogenic drive to the endometrium and myometrium, while minimizing vasomotor symptoms and bone loss associated with current treatments. An integrated neurokinin-kisspeptin system involving substance P and neurokinin B acting at the neurokinin (NK) receptors 1 and 3, respectively, modulates reproductive hormone secretion and represents a therapeutic target. This work aimed to assess the effect…
- Serum kisspeptin levels in polycystic ovary syndrome: A meta-analysis — Meta-analysis, 2021
To clarify the association of serum kisspeptin levels in women with polycystic ovary syndrome (PCOS) by meta-analysis. Two English databases and two Chinese databases were searched for the relationship between kisspeptin and PCOS published from 2009. After the studies screening according to specific principles, we used STATA 12.0 for meta-analysis. Standardized mean difference (SMD) and its 95% confidence intervals (95% CIs) were used as the effect size and STATA 12.0 softwar…
- Kisspeptin and its Current Clinical Status-A Systematic Review — Systematic review, 2025
Kisspeptin was initially known as metastin for its role in suppressing metastasis in melanoma and breast cancer. Later, based on its ability to stimulate GPR54, its importance in maintaining an intact hypothalamic-pituitary-ovarian axis was recognised, which is the basis for the widespread application of the drug in several conditions such as secondary amenorrhea, regulation of puberty onset, ovarian function, trophoblast invasion, fertility regulation, parturition, and lacta…
Evidence digest
What the research on Kisspeptin actually shows
The indexed literature on Kisspeptin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Kisspeptin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.597% | $3.50 (67%) | 2 | 99.2% | 3.7% | |
| PeptidePlugs | 89.790% | — | 2 | 99.7% | 5.7% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 1 | 99.8% | 0.0% | |
| NeuroLabs Research | 84.886% | $3.50 (67%) | 1 | 99.8% | 14.2% | |
| American PeptidesISO/IEC 17025 | 83.6100% | $6.00 (114%) | 1 | 99.9% | 0.5% | |
| Ascension Peptides | 79.186% | $5.00 (95%) | 1 | 99.8% | 0.2% | |
| Good Science Bio | 78.975% | $3.50 (67%) | 0 | — | — | |
| Licensed Peptides | 7789% | — | 1 | 99.8% | 0.6% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.5% | 7.0% | |
| Northline LabsISO/IEC 17025 | 72.393% | $10.00 (191%) | 1 | 99.7% | 4.0% | |
| GenX Peptides | 71.368% | $4.40 (84%) | 0 | — | — | |
| BioLongevity Labs | 67.474% | $6.50 (124%) | 0 | — | — | |
| Koi Peptides | 66.894% | $9.00 (171%) | 0 | — | — | |
| Mile High Compounds | 65.494% | — | 2 | 98.5% | 4.5% | |
| Eternal Peptides | 6565% | $5.50 (105%) | 0 | — | — | |
| Extreme Peptides | 64.282% | — | 1 | 99.4% | 0.0% |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| NeuroLabs Research | NL01-KISS10R | Analysis FreedomDiagnostics | 10 mg | 8.58 mg | 14.2% | 99.8% | Vendor-published | |
| PeptidePlugs | 160-07-DK | Freedom Diagnostics Testing | 10 mg | 9.46 mg | 5.4% | 99.8% | Vendor-published | |
| Next Gen Peptides | KSP02 | ILS Laboratories | 10 mg | 10.42 mg | 4.2% | 99.0% | Vendor-published | |
| Northline Labs | NLL-5606516 | ILS Laboratories | 10 mg | 10.4 mg | 4.0% | 99.7% | Vendor-published | |
| Modern Aminos | BX-P-I9Z0 | Analysis FreedomDiagnostics | 10 mg | 9.3 mg | 7.0% | 99.5% | Vendor-published | |
| American Peptides | KISS10-0528 | Bioviridian Inc. | 10 mg | 10.05 mg | 0.5% | 99.9% | Vendor-published | |
| PeptidePlugs | 126-02-SM | Freedom Diagnostics Testing | 10 mg | 9.4 mg | 6.0% | 99.5% | Vendor-published | |
| Next Gen Peptides | KSP01 | ILS Laboratories | 10 mg | 10.32 mg | 3.2% | 99.3% | Vendor-published | |
| Hydro Research Peptides | HY-KISS-T4Q7 | ILS Laboratories | 11.89 mg | 11.89 mg | 0.0% | 99.8% | Vendor-published | |
| Licensed Peptides | KISSPE-01 | Vanguard Laboratory | 5 mg | 5.03 mg | 0.6% | 99.8% | Vendor-published | |
| Extreme Peptides | EXT-KISS-00003 | Richard Sylvester MD | 5.9 mg | 5.9 mg | 0.0% | 99.4% | Vendor-published | |
| Ascension Peptides | 2025-06-10 | MZ Biolabs | 10 mg | 9.98 mg | 0.2% | 99.8% | Vendor-published | |
| Mile High Compounds | KSP-010-MH-02 | Independent Lab B | 10 mg | 9.6 mg | 4.0% | 98.0% | Vendor-published | |
| Mile High Compounds | KSP-010-MH-01 | Independent Lab A | 10 mg | 9.5 mg | 5.0% | 99.0% | Vendor-published |